secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2023-01-27T23:59:59+00:00
Accession:  0001193125-23-017765
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa enters ATM equity offering facility for up to $125M
------------------------------------------------------------

- Entered Sales Agreement with SVB Securities for at-the-market offering of ADS representing ordinary shares.
- Company may sell up to $125M of ADS at its discretion; no minimum offering amount required.
- SVB Securities to receive 3% commission on gross proceeds; company reimburses legal fees up to $150k.
- Net proceeds expected for working capital, capex, and general corporate purposes.
- No assurance of any sales; offering terminates upon full sale or agreement termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000119312523017765/0001193125-23-017765-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000119312523017765/d418242d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-017765

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer